Publication

Ku-dependent non-homologous end-joining as the major pathway contributes to sublethal damage repair in mammalian cells

Downloadable Content

Persistent URL
Last modified
  • 02/25/2025
Type of Material
Authors
    Min Liu, Jilin UniversitySolah Lee, Emory UniversityBailong Liu, Jilin UniversityHongyan Wang, Emory UniversityLihua Dong, Jilin UniversityYa Wang, Emory University
Language
  • English
Date
  • 2015-11-02
Publisher
  • Taylor & Francis
Publication Version
Copyright Statement
  • © 2015 Informa UK, Ltd.
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 0955-3002
Volume
  • 91
Issue
  • 11
Start Page
  • 867
End Page
  • 871
Grant/Funding Information
  • This work is supported by grants from the National Aeronautics and Space Administration (NNX11AC30G to Y.W.) and the National Cancer Institute (P30CA138292 to the Institute).
Abstract
  • Purpose: Sublethal damage repair (SLDR) is a type of repair that occurs in split dose irradiated cells, which was discovered more than 50 years ago. However, due to conflicting reported data, it remains unclear which DNA double strand break (DSB) repair pathway, non-homologous end-joining (NHEJ) repair, homologous recombination repair (HRR) or both, contributes to SLDR, particularly in human cells. We were interested in clarifying this question. Methods and materials: Mammalian cell lines, including human, mouse and Chinese hamster ovary (CHO) cell lines, wild type, deficient in NHEJ or HRR were irradiated with either single dose or two split doses at 2 or 4 hour intervals. The clonogenic assay was used to evaluate these cell radiosensitivities. Results: All wild type or HRR deficient cells (including human, mouse and CHO cells) showed a higher survival rate after exposure to split dose versus single dose radiation, however, all classical NHEJ deficient cells (including human, mouse and hamster cells) did not show any apparent sensitivity changes between single dose and split dose irradiation. Conclusion: Classical NHEJ mainly contributes to SLDR in mammalian cells (including human cells) cells. These results have the potential to improve radiotherapy.
Author Notes
  • Correspondence to: Ya Wang, MD, PhD, Department of Radiation Oncology, Emory University School of Medicine, 1365 Clifton Rd NE Suite 5090, Atlanta, GA 30322, USA, Tel: (404) 778-1832, Fax: (404) 778-1750, ywang94@emory.edu; Lihua Dong, MD, Department of Radiation Oncology, The First Hospital, Jilin University, 71 Xinmin Street, Changchun, 130021, China, Tel: 011 86 431-8878-2468, Fax: 011 86 431-8878-6172, drlhdong@163.com.
Keywords

Tools

Relations

In Collection:

Items